TB-500 Dosage | Chart and Protocol

TB-500 Dosage | Chart and Protocol. TB-500 dosage chart for research: compare loading and maintenance protocols, frequency, and 5mg/10mg vial reconstitution math. Key Takeaways The most commonly cited TB-500 dosage range is 4–8mg per week during a four-week loading phase , usually divided into two research exposures rather than treated as one large amount. Maintenance protocols commonly cite 2–4mg every two to four weeks , but this convention comes primarily from community practice—not a validated clinical dosing standard. Reconstitution changes volume, not peptide mass. A 5mg vial mixed with 2mL contains 2.5mg/mL; a 10mg vial mixed with 2mL contains 5mg/mL. TB-500 is a research peptide associated with the actin-binding region of thymosin beta-4. It is not an FDA-approved drug, and there is no approved human TB-500 protocol. This page is a chart and math reference, not a calculator or prescription. Combined-vial calculations belong in the dedicated BPC-157/TB-500 blend calculator. How much TB-500 per week? The TB-500 dosage most often cited in research-community protocols is 4–8mg per week for four weeks as a loading phase, followed by a less frequent maintenance amount. Those numbers are conventions reported outside an approved clinical framework: TB-500 has no FDA-approved indication, standardized human dose, or validated treatment schedule. This guide documents the convention so researchers can audit protocol claims and reconstitution math; it does not recommend administration or human use. The practical distinction is between peptide mass (milligrams per week), frequency (how that weekly total is divided in a protocol), and liquid volume (milliliters or U-100 syringe units after reconstitution). Mixing up those three values is the most common source of a tenfold calculation error. TB-500 Dosage Chart: Loading vs Maintenance The chart below summarizes amounts commonly cited in research and community protocol discussions. It is descriptive—not a clinical standard, prescription, or instruction for human dosing. Protocol phase Commonly cited total Commonly cited frequency Typical duration Evidence status Conservative loading 4mg per week Often divided into 2 research exposures 4 weeks Community convention; not clinically validated Higher loading 6–8mg per week Often divided into 2 research exposures 4 weeks Community convention; not clinically validated Maintenance 2–4mg total Every 2–4 weeks Protocol-dependent Community convention; not clinically validated No maintenance 0mg after loading Observation/washout phase Protocol-dependent Useful where the study design requires a defined endpoint A four-week loading protocol therefore totals 16mg at 4mg/week , 24mg at 6mg/week , or 32mg at 8mg/week . That vial-planning arithmetic is separate from deciding whether a protocol is scientifically justified. Published thymosin beta-4 research cannot automatically validate a branded or truncated TB-500 schedule because the identity, sequence, formulation, model, and route may differ. What Is TB-500? TB-500 is a synthetic peptide generally marketed as a fragment associated with thymosin beta-4 (Tβ4) , a 43-amino-acid actin-binding protein involved in cell migration, angiogenesis, and tissue-repair signaling. Vendor descriptions often connect TB-500 to the LKKTETQ active region of Tβ4. Researchers should verify the exact sequence and mass on the product documentation rather than assuming every vial labelled “TB-500” is chemically identical to full-length thymosin beta-4. That identity issue matters when interpreting studies. Evidence on the parent Tβ4 molecule supports hypotheses about mechanism, but it does not establish an approved TB-500 dose or prove that a commercial fragment reproduces every effect of the parent protein. Our TB-500 FDA status guide separates parent-compound research from regulatory approval. Loading Phase vs Maintenance Phase A loading phase front-loads a fixed weekly research amount over a short window, commonly four weeks. Protocols usually split the weekly total into two exposures to avoid treating “per week” and “per administration” as the same number. For example, a protocol recorded as 4mg/week may document two equal 2mg research exposures; 8mg/week may be recorded as two equal 4mg exposures. A maintenance phase reduces both total exposure and frequency. The commonly cited 2–4mg every two to four weeks is not equivalent to 2–4mg every week. A protocol record should state the amount, interval, start date, number of exposures, and cumulative total explicitly. “Monthly” is also imprecise: every four weeks equals 13 intervals per year, while once per calendar month equals 12. TB-500 Frequency: Why Protocols Split the Weekly Total Community protocols frequently divide loading totals into two weekly entries spaced several days apart. This is a documentation convention, not proof that twice-weekly exposure is pharmacologically optimal. Robust human pharmacokinetic data for TB-500 are not available to establish a clinical frequency, half-life target, or therapeutic window. For reproducible lab notes, write “weekly total ÷ number of exposures = amount per exposure” . A 6mg weekly total divided across two entries is 3mg per entry. Do not infer syringe units until vial strength and diluent volume are known. Reconstitution Math for 5mg and 10mg TB-500 Vials The core equations are: Concentration (mg/mL) = vial mass (mg) ÷ BAC water (mL) Volume (mL) = target research amount (mg) ÷ concentration (mg/mL) U-100 units = volume (mL) × 100 On a U-100 syringe, 100 units equals 1mL and one unit equals 0.01mL. The following table is arithmetic for typical 5mg and 10mg vials; it does not select a dose. Vial BAC water Concentration 1mg 2mg 4mg 5mg 1mL 5mg/mL 20 units 40 units 80 units 5mg 2mL 2.5mg/mL 40 units 80 units 160 units* 10mg 1mL 10mg/mL 10 units 20 units 40 units 10mg 2mL 5mg/mL 20 units 40 units 80 units 10mg 3mL 3.33mg/mL 30 units 60 units 120 units* *A value above 100 units exceeds a 1mL U-100 syringe. It is shown to make the concentration math transparent, not as a handling recommendation. Also confirm that the vial has enough total peptide: a 4mg aliquot consumes 80% of a 5mg vial. Worked example: 10mg vial plus 2mL BAC water 10mg ÷ 2mL = 5mg/mL . Each U-100 unit contains 0.05mg (50mcg). A 2mg research aliquot is 2 ÷ 5 = 0.4mL, or 40 units . The same 40-unit mark would represent a different mass if either the vial strength or water volume changed. TB-500 vs BPC-157: Systemic vs Local Research Rationale Comparison TB-500 BPC-157 Research identity Fragment associated with thymosin beta-4 15-amino-acid gastric peptide Common protocol rationale Often described as systemic because Tβ4-related signaling involves cell migration and actin regulation across tissues Often described as local or site-focused in community protocols Evidence caution Parent Tβ4 evidence is not the same as proof for every TB-500 product Evidence remains predominantly preclinical and does not establish an approved human protocol “Local” and “systemic” are useful shorthand for the rationale people cite, but they should not be treated as proven administration rules. No head-to-head clinical evidence establishes that one placement strategy is superior. For a vial containing both compounds, use the BPC-157/TB-500 blend dosage calculator ; it separates total blend mass into estimated per-compound amounts based on the labelled ratio. Research-Use and Legal Status TB-500 is not FDA approved for human therapeutic use , and a research-use label does not turn it into an approved medicine. It is also prohibited in sport under anti-doping rules. Purchase/possession rules, FDA drug approval, and athletic eligibility are separate frameworks. Review both TB-500 FDA approval status and whether TB-500 is legal before making claims about regulatory status. For comparison, BPC-157’s FDA status presents a similar distinction between preclinical interest and an approved drug. Frequently Asked Questions What is the commonly cited TB-500 loading dose? Research-community protocols most often cite 4–8mg total per week for four weeks, frequently split into two entries. This is an observed convention, not an approved or clinically validated human dose. What is the commonly cited TB-500 maintenance protocol? Common descriptions cite 2–4mg every two to four weeks after loading. Some research designs use no maintenance phase and instead define an observation or washout period. How many units is 2mg of TB-500? It depends on concentration. In a 10mg vial reconstituted with 2mL, 2mg equals 40 U-100 units. In a 5mg vial reconstituted with 2mL, the same 2mg equals 80 units. Is this a TB-500 dosage calculator? No. This is a static protocol and reconstitution chart. For combined BPC-157/TB-500 vial math, use the dedicated blend calculator linked above. References Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Ann N Y Acad Sci. 2012. PMID: 22074294 . Huff T, Müller CSG, Otto AM, Netzker R, Hannappel E. β-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol. 2001. PMID: 11312109 . Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide BPC 157 and musculoskeletal soft-tissue healing. Cell Tissue Res. 2019. PMID: 30915550 . PeptideStack page context: visitors can use the header navigation to reach the product catalog, blog, calculators, supplier pages, discount-code pages, contact page, legal policies, privacy policy, terms, and research disclaimer. The site is organized around research peptide education, supplier transparency, product comparison, vendor review content, discount-code tracking, and calculator tools for reconstitution or unit conversion research planning. PeptideStack separates research-use-only peptide information from FDA-approved medication and licensed telehealth pathways. Research peptide pages are informational and are not medical advice, prescription guidance, dosing instructions, treatment recommendations, or instructions for human consumption. Many pages include affiliate disclosures because PeptideStack may earn a commission when visitors click external supplier or telehealth links. That commission does not change the price paid by visitors and does not mean PeptideStack manufactures, sells, distributes, compounds, or ships peptides or medications. Supplier and product pages should be evaluated for third-party testing, batch-specific certificates of analysis, named laboratory verification, transparent pricing, realistic delivery expectations, payment security, refund policies, support quality, and consistent research-use-only labeling. Blog pages connect related guides, comparison articles, FDA approval status explainers, safety context, legality resources, product pages, vendor reviews, and calculator tools so visitors can keep researching without relying on a single supplier claim. Calculator pages are educational tools for laboratory planning and should be cross-checked against professional protocols, institutional requirements, and applicable laws. Legal and disclaimer pages explain the boundaries of PeptideStack content and the responsibility of visitors who evaluate third-party vendors. The rendered interface may add interactive details such as mobile navigation labels, product tabs, share buttons, related article cards, disclosure boxes, call-to-action buttons, vendor selectors, copy-code controls, email-code forms, footer navigation, and status labels. The static HTML fallback includes this context so the same page purpose is understandable before the JavaScript application finishes loading. Visitors should treat PeptideStack as a research and comparison starting point. Final supplier evaluation should include direct review of the external vendor website, current product availability, checkout terms, applicable laws, institutional requirements, and any third-party laboratory documentation available for the exact product or batch being considered. Footer resources repeat important sitewide context: PeptideStack is independent, affiliate-supported, research-focused, and not a pharmacy or manufacturer. Pages may include links to the iOS app, calculators, blog hubs, product hubs, supplier comparisons, support contact, and policy documents. This repeated context is intentionally available in the raw HTML for crawlers that inspect a page before executing the React bundle. Raw HTML also includes page summaries for mobile crawlers using JavaScript rendering, desktop crawlers comparing source to rendered output, accessibility tools, and no-script visitors. The fallback is replaced by the React app in normal browsers but keeps the source document aligned with the visible page topic. This fallback keeps source HTML and rendered HTML closer for crawl diagnostics and SEO audits across crawled pages, routes, reports, and recrawls.